Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death
Open Access
- 24 January 2019
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (7) , 1428-1439
Abstract
Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphomas are tumors that carry translocations involving the ALK gene at the 2p23 locus, leading to the expression of ALK tyrosine kinase fusion oncoproteins. Amongst hematological malignancies, these lymphomas are particular in that they express very low levels of B-Cell Lymphoma 2 (BCL2), a recognized inhibitor of apoptosis and autophagy, two processes that share complex interconnections. We have previously shown that treatment of ALK-positive anaplastic large cell lymphoma cells with the ALK tyrosine kinase inhibitor crizotinib induces autophagy as a pro-survival response. Here, we observed that crizotinib-mediated inactivation of ALK caused an increase in BCL2 levels that restrained the cytotoxic effects of the drug. BCL2 downregulation in combination with crizotinib treatment potentiated loss of cell viability through both an increase in autophagic flux and cell death, including apoptosis. More importantly, our data revealed that the blockade of autophagic flux completely reversed impaired cell viability, which demonstrates that excessive autophagy is associated with cell death. We propose that the downregulation of BCL2 protein, which plays a central role in the autophagic and apoptotic machinery, combined with crizotinib treatment may represent a promising therapeutic alternative to current ALK-positive anaplastic large cell lymphoma treatments.Keywords
This publication has 49 references indexed in Scilit:
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- The Development of an Immunohistochemical Method to Detect the Autophagy-Associated Protein LC3-II in Human Tumor XenograftsToxicologic Pathology, 2011
- The Double-Edged Sword of Autophagy Modulation in CancerClinical Cancer Research, 2009
- Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for AutophagyMolecular Biology of the Cell, 2009
- Bcl-2 family proteins and cancerOncogene, 2008
- The anaplastic lymphoma kinase in the pathogenesis of cancerNature Reviews Cancer, 2008
- Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent AutophagyCell, 2005
- High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphomaJournal of Clinical Pathology, 2005
- Bcl-2 Expression in Anaplastic Large Cell LymphomaThe American Journal of Pathology, 2001
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's LymphomaScience, 1994